<SEC-DOCUMENT>0001477932-17-003016.txt : 20170627
<SEC-HEADER>0001477932-17-003016.hdr.sgml : 20170627
<ACCEPTANCE-DATETIME>20170627163018
ACCESSION NUMBER:		0001477932-17-003016
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170623
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170627
DATE AS OF CHANGE:		20170627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55532
		FILM NUMBER:		17932694

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ctxr_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>

<html><head><title>ctxr_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="center">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><font size="3">UNITED STATES</font></b></p>
<p style="MARGIN: 0px" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p style="MARGIN: 0px" align="center"><b><font size="3">Washington, D.C. 20549</font></b></p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><font size="5">FORM 8-K</font></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">CURRENT REPORT</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Pursuant to Section 13 or 15(d) of</p>
<p style="MARGIN: 0px" align="center">the Securities Exchange Act of 1934</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported) <u><b>June 23, 2017</b></u></p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="45%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><b><font size="5">Citius Pharmaceuticals, Inc.</font></b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in its charter)</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u><b>Nevada</b></u></p>
<p style="MARGIN: 0px" align="center">(State or other jurisdiction of incorporation)</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="left">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="3" cellpadding="0" width="85%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid" width="45%">
<p style="MARGIN: 0px" align="center"><b>333-206903</b></p></td>
<td width="10%">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" width="45%">
<p style="MARGIN: 0px" align="center"><b>27-3425913</b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center">(Commission File Number)</p></td>
<td>
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="center">(IRS Employer Identification No.)</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><b>11 Commerce Drive, 1st Floor </b></p>
<p style="MARGIN: 0px" align="center"><b>Cranford, NJ</b></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="center"><b>07016</b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center">(Address of principal executive offices)</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="center">(Zip Code)</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Registrant&#8217;s telephone number, including area code <u><b>(908) 967-6677 </b></u></p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
<p style="MARGIN: 0px"><font face="Wingdings">&#168; </font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="MARGIN: 0px"><font face="Wingdings">&#168; </font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="MARGIN: 0px"><font face="Wingdings">&#168; </font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Emerging growth company &#9744; </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">
<table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On June 23, 2017, Citius Pharmaceuticals, Inc. (the &#8220;<b><i>Company</i></b>&#8221;) executed a convertible future advance promissory note in favor of Leonard Mazur (&#8220;<b><i>Lender</i></b>&#8221;) in the principal amount of up to $1,000,000 (the &#8220;<b><i>Bridge Note</i></b>&#8221;). The Company may draw on the Bridge Note as needed up to the $1,000,000 principal amount, of which $590,000 is outstanding under the Bridge Note as of June 27, 2017. The Bridge Note bears interest at the &#8220;Prime Rate&#8221; as published in the Wall Street Journal on the last day of each relevant month plus 1%, and matures on the earlier of December 31, 2017 or the full conversion of the Bridge Note. The Bridge Note is convertible, in whole or in part, into shares of the Company&#8217;s common stock at a conversion price equal to 75% of the price per share paid by investors in the Company&#8217;s contemplated securities offering pursuant to a Form S-1 registration statement (File No. 333-217956) filed with the U.S. Securities and Exchange Commission. In addition, in the event the Company enters into a debt financing with a third party on terms better than those of the Bridge Note while such Bridge Note remains outstanding, the Company will notify Lender of such terms and Lender may elect, in Lender&#8217;s sole discretion, to amend the Bridge Note to incorporate such terms. The Bridge Note is governed by the same form of agreement governing the convertible future advance promissory note executed in favor of Leonard Mazur on May 10, 2017 for $1,500,000 and filed as Exhibit 10.1 to the Company&#8217;s Form 10-Q for the fiscal quarter ended March 31, 2017 (the &#8220;<b><i>Form of Bridge Note</i></b>&#8221;).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Lender, Leonard Mazur, is our Executive Chairman and Secretary and a director of the Company.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The foregoing description is a summary only, does not purport to set forth the complete terms of the Bridge Note, and is qualified in its entirety by reference to the Form of Bridge Note filed as Exhibit 10.1 to the Company&#8217;s Form 10-Q for the fiscal quarter ended March 31, 2017 which is incorporated by reference herein.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Item 9.01. Financial Statements and Exhibits</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">(d) <i>Exhibits.</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="8%">
<p style="MARGIN: 0px" align="justify"><b>Exhibit No.</b></p></td>
<td width="2%">&nbsp;</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="justify"><b>Description of Exhibit</b></p></td></tr>
<tr height="15">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">10.1</p></td>
<td valign="top">&nbsp;</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Future Advance Convertible Promissory Note dated May 10, 2017 between Leonard Mazur and the Company (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q for the fiscal quarter ended March 31, 2017).</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreake1389058-f2c1-4e2a-8021-d0adf283902d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURE</b><b><u></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>&nbsp;</td>
<td colspan="2"><b>CITIUS PHARMACEUTICALS, INC.</b></td>
<td></td></tr>
<tr>
<td width="50%">&nbsp;</td>
<td width="3%">&nbsp;</td>
<td width="35%">&nbsp;</td>
<td width="12%">&nbsp;</td></tr>
<tr>
<td>Date: June 27, 2017</td>
<td>By:</td>
<td style="BORDER-BOTTOM: black 1px solid"><em>/s/ Myron Holubiak</em></td>
<td></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>Myron Holubiak</td>
<td>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>President and Chief Executive Officer</td>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">3</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
